Evidence map›Paper›PMID 29968520›Full record

ReviewBioengineered2018

CRISPR-Cas systems: ushering in the new genome editing era.

Fernando Perez Rojo, Rikard Karl Martin Nyman, Alexander Arthur Theodore Johnson, Maria Pazos Navarro, Megan Helen Ryan, William Erskine, Parwinder Kaur

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bioengineered, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. CRISPR-Cas9 in the Tailoring of Genetically Engineered Animals.Current issues in molecular biology · 2025
    Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. An Improved Protocol forInternational journal of molecular sciences · 2021
    Article
  14. Various Aspects of a Gene Editing System-CRISPR-Cas9.International journal of molecular sciences · 2020
    Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Cause or casualty: The role of mitochondrial DNA in aging and age-associated disease.Biochimica et biophysica acta. Molecular basis of disease · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fernando Perez Rojoa Centre for Plant Genetics and Breeding, School of Agriculture and Environment , The University of Western Australia , Crawley , WA , Australia.ORCID 0000-0001-9513-5116
Rikard Karl Martin Nymana Centre for Plant Genetics and Breeding, School of Agriculture and Environment , The University of Western Australia , Crawley , WA , Australia.ORCID 0000-0002-6094-392X
Alexander Arthur Theodore Johnsonb School of BioSciences , The University of Melbourne , Victoria , Australia.ORCID 0000-0002-1209-6447
Maria Pazos Navarroa Centre for Plant Genetics and Breeding, School of Agriculture and Environment , The University of Western Australia , Crawley , WA , Australia.ORCID 0000-0001-8319-3570
Megan Helen Ryanc Institute of Agriculture , The University of Western Australia , Crawley , WA , Australia.
William Erskinea Centre for Plant Genetics and Breeding, School of Agriculture and Environment , The University of Western Australia , Crawley , WA , Australia.
Parwinder Kaura Centre for Plant Genetics and Breeding, School of Agriculture and Environment , The University of Western Australia , Crawley , WA , Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years there has been great progress with the implementation and utilization of Clustered Regularly Interspaced Palindromic Repeats (CRISPR) and CRISPR-associated protein (Cas) systems in the world of genetic engineering. Many forms of CRISPR-Cas9 have been developed as genome editing tools and techniques and, most recently, several non-genome editing CRISPR-Cas systems have emerged. Most of the CRISPR-Cas systems have been classified as either Class I or Class II and are further divided among several subtypes within each class. Research teams and companies are currently in dispute over patents for these CRISPR-Cas systems as numerous powerful applications are concurrently under development. This mini review summarizes the appearance of CRISPR-Cas systems with a focus on the predominant CRISPR-Cas9 system as well as the classifications and subtypes for CRISPR-Cas. Non-genome editing uses of CRISPR-Cas are also highlighted and a brief overview of the commercialization of CRISPR is provided.

Indexed as

Clustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsGenomeAnimalsAnimals, Genetically ModifiedCRISPR-Associated Protein 9DNADNA End-Joining RepairGene EditingHumansPatents as TopicPlantsPlants, Genetically ModifiedRNA, Guide, CRISPR-Cas SystemsTranscription Activator-Like Effector NucleasesCRISPR-Associated Protein 9DNARNA, Guide, CRISPR-Cas SystemsTranscription Activator-Like Effector NucleasesCas13Cas9Cas classesCas typesCRISPR-Cas figureCRISPR productsgenome editingHDRNHEJTALENZFN

Identifiers

PMID29968520
PMCPMC6067892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.